Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention

Author(s): Bo Zhao, Guang-Ping Li*, Jian-Jun Peng, Li-Hui Ren, Li-Cheng Lei, Hui-Ming Ye, Zuo-Yan Wang and Sheng Zhao

Volume 22, Issue 4, 2021

Published on: 29 June, 2020

Page: [549 - 556] Pages: 8

DOI: 10.2174/1389201021666200629153421

Price: $65

Abstract

Objective: ST-Segment Elevation Myocardial Infarction (STEMI) patients with the multivessel disease have distinctive plaque characteristics in non-IRA lesions. Intensive statin therapy was a potential approach to treat STEMI patients with the non-IRA disease. However, there is still poor evidence about the therapeutic effect. In this study, we have evaluated the detailed therapeutic effect of statin plus ezetimibe intensive therapy.

Methods: For STEMI patients with non-IRA disease undergoing primary Percutaneous Coronary Intervention (PCI), 183 control STEMI patients without non-IRA disease undergoing primary PCI, and 200 STEMI patients with non-IRA disease undergoing primary PCI were introduced into this study. 200 STEMI patients with non-IRA disease undergoing primary PCI were divided into Normal group, Intensive group, Normal & Combined group, and Intensive & Combined group. The baseline information for each participant was recorded. Meanwhile, the physiological and biochemical indicators of each member with different treatments were collected after one-year follow-up.

Results: For STEMI patients with non-IRA disease undergoing primary PCI, no differences could be detected in multiple indexes such as OCT examination results, age, stroke, etc. However, diabetes mellitus, smoking, and coronary Gensini score were different between different groups (P<0.05). After one year follow-up, cholesterol, low-density lipoprotein, coronary Gensini score, thin-cap fibroatheroma, length of non-infarcted arterial lesions, non-infarct artery lesion range, myocardial infarction again, and revascularization again were significantly different between different groups (P<0.05).

Conclusion: The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach for STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel method for the treatment of STEMI patients with non-IRA disease undergoing primary PCI.

Keywords: STEMI, IRA, PCI, pitavastatin, ezetimibe, cardiology.

« Previous Next »
Graphical Abstract

[1]
Slavich, M.; Patel, R.S. Coronary artery spasm: Current knowledge and residual uncertainties. Int. J. Cardiol. Heart Vasc., 2016, 10, 47-53.
[http://dx.doi.org/10.1016/j.ijcha.2016.01.003] [PMID: 28616515]
[2]
Zhang, X.H.; Lu, Z.L.; Liu, L. Coronary heart disease in China. Heart, 2008, 94(9), 1126-1131.
[http://dx.doi.org/10.1136/hrt.2007.132423] [PMID: 18703693]
[3]
Nelson, R.H. Hyperlipidemia as a risk factor for cardiovascular disease. Prim. Care, 2013, 40(1), 195-211.
[http://dx.doi.org/10.1016/j.pop.2012.11.003] [PMID: 23402469]
[4]
Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; Watts, G.F.; Borén, J.; Fazio, S.; Horton, J.D.; Masana, L.; Nicholls, S.J.; Nordestgaard, B.G.; van de Sluis, B.; Taskinen, M.R.; Tokgözoglu, L.; Landmesser, U.; Laufs, U.; Wiklund, O.; Stock, J.K.; Chapman, M.J.; Catapano, A.L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J., 2017, 38(32), 2459-2472.
[http://dx.doi.org/10.1093/eurheartj/ehx144] [PMID: 28444290]
[5]
Banning, A.S.; Gershlick, A.H. Management of multivessel coronary cisease in sT-segment elevation myocardial infarction. Curr. Cardiol. Rep., 2015, 17(9), 632.
[http://dx.doi.org/10.1007/s11886-015-0632-6] [PMID: 26238745]
[6]
Kotani, J.; Mintz, G.S.; Castagna, M.T.; Pinnow, E.; Berzingi, C.O.; Bui, A.B.; Pichard, A.D.; Satler, L.F.; Suddath, W.O.; Waksman, R.; Laird, J.R., Jr; Kent, K.M.; Weissman, N.J. Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. Circulation, 2003, 107(23), 2889-2893.
[http://dx.doi.org/10.1161/01.CIR.0000072768.80031.74] [PMID: 12782565]
[7]
Sahin, D.Y.; Gür, M.; Elbasan, Z.; Yıldız, A.; Kaya, Z.; Içen, Y.K.; Kıvrak, A.; Türkoğlu, C.; Yılmaz, R.; Caylı, M. Predictors of preinterventional patency of infarct-related artery in patients with ST-segment elevation myocardial infarction: Importance of neutrophil to lymphocyte ratio and uric acid level. Exp. Clin. Cardiol., 2013, 18(2), e77-e81.
[PMID: 23940451]
[8]
Libby, P. Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med., 2013, 368(21), 2004-2013.
[http://dx.doi.org/10.1056/NEJMra1216063] [PMID: 23697515]
[9]
Elbasan, Z.; Gur, M.; Sahin, D.Y. The effect of chronic statin use on patency of infarct related artery in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur. Heart J., 2013, 34(Suppl. 1), 1274.
[http://dx.doi.org/10.1093/eurheartj/eht308.P1274]
[10]
Wang, J.; Tokoro, T.; Higa, S.; Kitajima, I. Anti-inflammatory effect of pitavastatin on NF-kappaB activated by TNF-α in hepatocellular carcinoma cells. Biol. Pharm. Bull., 2006, 29(4), 634-639.
[http://dx.doi.org/10.1248/bpb.29.634] [PMID: 16595893]
[11]
Park, S.; Kang, H.J.; Rim, S.J.; Ha, J.W.; Oh, B.H.; Chung, N.; Cho, S.Y. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin. Ther., 2005, 27(7), 1074-1082.
[http://dx.doi.org/10.1016/j.clinthera.2005.07.007] [PMID: 16154486]
[12]
Alagona, P. Jr Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid., 2010, 5, 91-105.
[http://dx.doi.org/10.2147/CE.S8008] [PMID: 21468365]
[13]
Knopp, R.H; Gitter, H; Truit, T Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia Europ Heart J., 2003, 12(4), 36-37.,
[14]
Blazing, M.A.; Giugliano, R.P.; Cannon, C.P.; Musliner, T.A.; Tershakovec, A.M.; White, J.A.; Reist, C.; McCagg, A.; Braunwald, E.; Califf, R.M. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am. Heart J., 2014, 168(2), 205-12.e1.
[http://dx.doi.org/10.1016/j.ahj.2014.05.004] [PMID: 25066560]
[15]
Li, J.; Li, X.; Hu, S.; Yu, Y.; Yan, X.F.; Jiang, L.X. ST-segment elevation myocardial infarction in the eastern urban China: From 2001 to 2011. Zhonghua Xin Xue Guan Bing Za Zhi, 2016, 44(4), 303-308.
[PMID: 27112607]
[16]
Zhang, H.P.; Zhao, Y.; Li, H.; Tang, G.D.; Ai, H.; Zheng, N.X.; Liu, J.H.; Sun, F.C. Impact of chronic total occlusion in a noninfarct- related artery on clinical outcomes in patients with acute STelevation myocardial infarction undergoing primary percutaneous coronary intervention. Medicine (Baltimore), 2016, 95(2), e2441..
[http://dx.doi.org/10.1097/MD.0000000000002441] [PMID: 26765429]
[17]
Ikenaga, H.; Ishihara, M.; Inoue, I.; Kawagoe, T.; Shimatani, Y.; Miura, F.; Nakama, Y.; Dai, K.; Otani, T.; Ejiri, K.; Oda, N.; Nakamura, M.; Miki, T. Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ. J., 2011, 75(12), 2847-2852.
[http://dx.doi.org/10.1253/circj.CJ-11-0365] [PMID: 21914962]
[18]
Nozue, T.; Yamamoto, S.; Tohyama, S.; Fukui, K.; Umezawa, S.; Onishi, Y.; Kunishima, T.; Sato, A.; Nozato, T.; Miyake, S.; Takeyama, Y.; Morino, Y.; Yamauchi, T.; Muramatsu, T.; Hibi, K.; Terashima, M.; Michishita, I. Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectoris. Lipids Health Dis., 2014, 13(1), 59.
[http://dx.doi.org/10.1186/1476-511X-13-59] [PMID: 24684829]
[19]
McCann, G.P.; Khan, J.N.; Greenwood, J.P.; Nazir, S.; Dalby, M.; Curzen, N.; Hetherington, S.; Kelly, D.J.; Blackman, D.J.; Ring, A.; Peebles, C.; Wong, J.; Sasikaran, T.; Flather, M.; Swanton, H.; Gershlick, A.H. Complete versus lesion-only primary PCI: The randomized cardiovascular MR CvLPRIT substudy. J. Am. Coll. Cardiol., 2015, 66(24), 2713-2724.
[http://dx.doi.org/10.1016/j.jacc.2015.09.099] [PMID: 26700834]
[20]
Sedlis, S.P.; Hartigan, P.M.; Teo, K.K.; Maron, D.J.; Spertus, J.A.; Mancini, G.B.; Kostuk, W.; Chaitman, B.R.; Berman, D.; Lorin, J.D.; Dada, M.; Weintraub, W.S.; Boden, W.E. COURAGE Trial Investigators. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N. Engl. J. Med., 2015, 373(20), 1937-1946.
[http://dx.doi.org/10.1056/NEJMoa1505532] [PMID: 26559572]
[21]
Brooks, M.M.; Chaitman, B.R.; Nesto, R.W. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the bARI 2D trial. Circulation, 2012, 126(17), 2115-2124.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.092973] [PMID: 23008442]
[22]
Widimsky, P.; Holmes, D.R. Jr How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur. Heart J., 2011, 32(4), 396-403.
[http://dx.doi.org/10.1093/eurheartj/ehq410] [PMID: 21118854]
[23]
Nico, H.J.P. Pepijn van S, Ganesh M. Percutaneous coronary intervention of functionally nonsignificant stenosis. J. Am. Coll. Cardiol., 2007, 49, 2105-2111.
[http://dx.doi.org/10.1016/j.jacc.2007.01.087]
[24]
Ikenaga, H.; Ishihara, M.; Inoue, I. Statin reduces cardiac events after acute myocardial infarction in patients with high lipoprotein (a). Circulation, 2010, (21)A13258
[25]
Räber, L.; Taniwaki, M.; Zaugg, S.; Kelbæk, H.; Roffi, M.; Holmvang, L.; Noble, S.; Pedrazzini, G.; Moschovitis, A.; Lüscher, T.F.; Matter, C.M.; Serruys, P.W.; Jüni, P.; Garcia-Garcia, H.M.; Windecker, S. IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators (NCT00962416). Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur. Heart J., 2015, 36(8), 490-500.
[http://dx.doi.org/10.1093/eurheartj/ehu373] [PMID: 25182248]
[26]
Ge, L.; Wang, J.; Qi, W.; Miao, H.H.; Cao, J.; Qu, Y.X.; Li, B.L.; Song, B.L. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab., 2008, 7(6), 508-519.
[http://dx.doi.org/10.1016/j.cmet.2008.04.001] [PMID: 18522832]
[27]
Vavlukis, M.; Vavlukis, A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context, 2018.7212534
[http://dx.doi.org/10.7573/dic.212534] [PMID: 30023003]
[28]
Ose, L. Pitavastatin: finding its place in therapy. Ther. Adv. Chronic Dis., 2011, 2(2), 101-117.
[http://dx.doi.org/10.1177/2040622310389227] [PMID: 23251745]
[29]
Sharma, A.; Sun, J-L.; Lokhnygina, Y.; Roe, M.T.; Ahmad, T.; Desai, N.R.; Blazing, M.A. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). Am. J. Cardiol., 2019, 123(8), 1193-1201.
[http://dx.doi.org/10.1016/j.amjcard.2019.01.034] [PMID: 30739657]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy